首页> 外文期刊>Epilepsy research >A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV)
【24h】

A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV)

机译:在新的抗癫痫药物和设备XIV会议上提出的数据摘要(EILAT XIV)

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV) took place in Madrid, Spain from May 13th to 16th 2018. Again, presentations on new medical devices and neuromodulation and discussions on device-related regulatory aspects were included in the programme. The virtual special issue on "neuromodulation" summarises the presentations focusing firstly, on the pre-clinical developments and the difficulties of clinical trial designs for neuromodulatory therapies, including vagus nerve stimulation (VNS) and Brain-Responsive Neurostimulation (RNS), and the use of transcutaneous vagus nerve stimulation (tVNS) as a potential screening tool for determining the efficacy of neuromodulatory treatments in individual patients; secondly, on wearable devices for seizure monitoring through indices of peripheral sympathetic nervous activity, the use of such devices in combination with biofeedback for the treatment of epilepsy, and its potential for improving epilepsy specialist services, particularly in remote areas.
机译:2018年5月13日至16日的西班牙马德里举行了新的抗癫痫药物和设备(EILAT XIV)的第十四届埃拉特会议。再次,该计划中纳入了关于新医疗设备和神经调节和对设备有关的监管方面的讨论的介绍。 “神经调节”的虚拟特殊问题总结了介绍,首先关注临床前发展和神经调节疗法的临床试验设计的困难,包括迷走神经刺激(VNS)和脑敏感的神经刺激(RNS)以及使用经皮迷走神经刺激(TVNS)作为用于确定个体患者中神经调节治疗的疗效的潜在筛选工具;其次,通过外周交感神经活动索引的可穿戴装置进行癫痫发作监测,使用这些装置与生物反馈用于治疗癫痫的生物融合,以及其改善癫痫专家服务的潜力,特别是在偏远地区。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号